Tags : Merger


Sorrento to Acquire ACEA Therapeutics for ~$488M

Shots: ACEA to receive up to ~$38M in shares of Sorrento common stock, $450M as additional payments upon the achievement of clinical & sales milestones along with 5 – 10% royalties based on annual sales of each product. The acquisition is expected to close in Q2’ 21 The acquisition includes Abivertinib, AC0058, AC0939, and ACEA’s […]Read More


23andMe Going Public Via Virgin Group SPAC Merger

Shots: 23andMe signs a SPAC merger with VGAC for an enterprise value of ~$3.5B, including $509M in cash in trust account and $250M PIPE of common stock at $10.00/share If no public shareholders of VGAC exercise their redemption rights, 23andMe will be capitalized up to $984M in cash to fund operations & support growth initiatives. […]Read More


The European Commission Approves the Merger of Mylan and Upjohn

Shots: The EC has approved the Viatris merger (a merger b/w Upjohn and Mylan) under EU merger regulations but the decision is conditional on the divestment of Mylan’s certain generic therapies EC ensures that the merger does not harm competition and preserves the competitive access to certain genericized therapies for national health services and the […]Read More


Oncternal Therapeutics Reverse Merges with GTx

Shots: With the closure of the transaction, Oncternal Therapeutics will be listed on Nasdaq under the ticker ONCT Oncternal’s stockholders will hold 75% of the shares of combined company and GTx will retain 25% of shares. GTx stockholders will receive 50% non-transferable contingent value rights (CVR) from the grant, sale or transfer of rights to […]Read More